Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Wakunaga Pharmaceutical Co., Ltd.
Dicentra Inc.
Information provided by (Responsible Party):
The Canadian College of Naturopathic Medicine
ClinicalTrials.gov Identifier:
NCT01887834
First received: June 25, 2013
Last updated: April 10, 2014
Last verified: April 2014
  Purpose

The Canadian College of Naturopathic Medicine is conducting a research study on Irritable Bowel Syndrome (IBS), a common condition in North America. It is a long term, recurring gastrointestinal disorder that is estimated to affect 30% of the general population. IBS is characterized by abdominal pain and cramps, and bowel dysfunction such as diarrhea and bloating.

The medicines that are currently used to help people with IBS are not as effective as we would like them to be. These medicines are usually only prescribed to reduce the pain of IBS and not actually treat the disorder itself. Recently, scientists have found that probiotics (beneficial bacteria that live inside humans) may help reduce the painful symptoms and diarrhea that are part of IBS.

This research is being conducted to determine whether this particular combination of three probiotic bacteria (named Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum) will reduce the symptoms of severe IBS.


Condition Intervention Phase
Irritable Bowel Syndrome
Digestive System Diseases
Colonic Diseases, Functional
Colitis, Mucous
Colon, Irritable
Dietary Supplement: Kyodophilus multi-strain probiotic capsules
Dietary Supplement: Kyodophilus Matching Placebo Capsules
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Severe Irritable Bowel Syndrome

Resource links provided by NLM:


Further study details as provided by The Canadian College of Naturopathic Medicine:

Primary Outcome Measures:
  • Irritable Bowel Syndrome Severity [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Irritable bowel severity scoring system is a validated questionnaire used to monitor IBS (Francis et al, 1997).


Secondary Outcome Measures:
  • Tolerability of the treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    A standardized Adverse Events Reporting Form will be used to query subjects on the incidence of any side effects, which will be recorded.


Other Outcome Measures:
  • The Irritable Bowel Syndrome-Quality of Life Questionnaire [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    This is a validated quality of life questionnaire (Patrick et al, 1998)

  • Adequate Response Criteria [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The Adequate Response criteria assesses the overall clinical relevance of the intervention under investigation: e.g. "In the past 7 days, have you had adequate relief (AR) of your IBS pain and discomfort?" (Ko et al, 2011; Guglielmetti et al, 2011; Ligaarden et al, 2010; Sondergaard et al, 2011)


Estimated Enrollment: 100
Study Start Date: June 2013
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Kyodophilus matching placebo capsules

Kyodophilus Matching Placebo Capsules

Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Dietary Supplement: Kyodophilus Matching Placebo Capsules
Active Comparator: Kyodophilus multi strain probiotic capsules

Kyodophilus multi-strain probiotic capsules

The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:

  • Lactobacillus gasseri KS-13 1.2
  • Bifidobacterium bifidum G9-1 0.15
  • Bifidobacterium longum MM-2 0.15

Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Dietary Supplement: Kyodophilus multi-strain probiotic capsules

Detailed Description:

The purpose of this trial is to investigate the effects of the three strain probiotic, Kyo-Dophilus, on the symptoms associated with severe Irritable Bowel Syndrome. A previous pilot clinical trial identified individuals with severe IBS to be most likely to benefit from the treatment provided in this trial.

The primary objective of this trial is to determine the effectiveness of Kyo-Dophilus on the symptoms associated with Irritable Bowel Syndrome in an adult population diagnosed with Irritable Bowel Syndrome by ROME III criteria and classified as severe through the Irritable Bowel Severity Scoring System and to measure quality of life and global well-being of patients through the Adequate Relief Criteria and the Irritable Bowel Syndrome-Quality of Life Questionnaire.

The secondary objective is to assess the tolerability of the treatment through the use of Adverse Event Reporting Forms.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects aged 18-64.
  • A diagnosis of Irritable Bowel Syndrome as per ROME III criteria.
  • A classification of severe irritable bowel syndrome as indicated by the Irritable Bowel Severity Scoring System (score >300).
  • Female subjects currently using an acceptable form of birth control who agree to maintain its use throughout the study (e.g. abstinence, oral contraceptives, barrier methods).
  • Subjects who agree to maintain their current eating habits throughout the study.
  • Ability to understand and sign the Informed Consent Form.

Exclusion Criteria:

  • Female subjects who are breastfeeding, pregnant, or are open to becoming pregnant in the next three months
  • Subjects currently receiving medication for the treatment of IBS symptoms.
  • Subjects currently receiving natural health products for treatment of IBS symptoms will be eligible for inclusion in the trial is they agree to undergo a four week washout period.
  • Subjects currently experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal pain.
  • Subjects who are immune-compromised (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment).
  • Subjects currently receiving antibiotic therapy or antibiotic therapy within the previous month.
  • Subjects regularly (>3 times weekly) consuming probiotics enriched products (e.g. probiotic enriched yogurts, Activia, etc…).
  • Subjects who have recently (< 3 months) initiated dietary measures to control IBS symptoms, such as elimination of certain foods.
  • Subjects with a history of major or complicated gastrointestinal surgery.
  • Subjects with severe endometriosis.
  • Subjects with malignant tumors or subjects undergoing chemotherapy or radiation therapy.
  • Subjects with severe IBS that require medication for treatment of IBS symptoms.
  • Subjects with weight loss, anemia, inflammatory bowel disease, or celiac sprue, and family history of colorectal cancer.
  • Subjects exhibiting or indicating thoughts of suicide currently or in the past as based on patient screening interview by the investigator/clinician. Appropriate referral to a health care provider will be provided.
  • Subjects with known allergies to milk or milk based products.
  • Subjects using and/or have used antipsychotic or anticholinergic medication within the prior month, those with reported significant abnormalities on thyroid function tests, blood counts and serum chemistry.
  • Subjects 50 years or older who have been diagnosed with IBS and have not received a colonoscopy in the last five years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01887834

Locations
Canada, Ontario
The Canadian College of Naturopathic Medicine
Toronto, Ontario, Canada, M2K 1E2
Sponsors and Collaborators
The Canadian College of Naturopathic Medicine
Wakunaga Pharmaceutical Co., Ltd.
Dicentra Inc.
Investigators
Principal Investigator: Dugald Seely, ND The Canadian College of Naturopathic Medicine
  More Information

No publications provided

Responsible Party: The Canadian College of Naturopathic Medicine
ClinicalTrials.gov Identifier: NCT01887834     History of Changes
Other Study ID Numbers: 1302
Study First Received: June 25, 2013
Last Updated: April 10, 2014
Health Authority: Canada: Health Canada

Keywords provided by The Canadian College of Naturopathic Medicine:
bloating
constipation
diarrhea
gas
mucous
cramping

Additional relevant MeSH terms:
Colonic Diseases
Colonic Diseases, Functional
Digestive System Diseases
Gastrointestinal Diseases
Irritable Bowel Syndrome
Syndrome
Disease
Intestinal Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on October 30, 2014